[Treatment and prognosis analysis of primary parotid squamous cell carcinoma].
OBJECTIVE
To investigate the prognosis-related factors and treatment strategy of primary parotid squamous cell carcinoma.


METHODS
Forty-nine primary parotid squamous cell carcinoma treated from 1970 to 2005 were retrospectively analyzed. The follow up data were analyzed by SPSS 13.0 software.


RESULTS
Integrated follow up data were obtained from 44 patients with a median follow up time of 38 months (5 - 215 months). Recurrence or distant metastasis of the carcinoma occurred in 21 patients, including 13 local recurrence in parotid or neck and 8 distant metastasis. Local recurrence was the main reason of treatment failure. The 3-year and 5-year survival rate and disease-free survival rate was 52%, 27% and 34%, 16%. Kaplan-Meier and log-rank analysis indicated that age, tumor size, distant metastasis, postoperative radiotherapy, facial nerve dysfunction, neck dissection, skin invasion, and surgical margins were prognosis-related factors. Cox analysis showed that age, facial nerve dysfunction, distant metastasis and surgical margins were the important factors that influenced the prognosis.


CONCLUSIONS
Primary parotid gland squamous cell carcinoma is an uncommon tumor, surgery and postoperative radiotherapy are the optimal treatment, which can improve the prognosis of the patients and decrease recurrence of the tumor.
Yao
Xiao-feng
XF
Department of Head and Neck Surgery, Tianjin Medical University, Tianjin 300060, China. yaoxiaofeng1980@yahoo.com.cn
Zhang
Lun
L
D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D037981:Neck Dissection; D009364:Neoplasm Recurrence, Local; D010306:Parotid Gland; D010307:Parotid Neoplasms / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D035583:Rare Diseases / Q000473:pathology / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate; D017211:Treatment Failure; D047368:Tumor Burden